Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research from Lidia Vasilieva's lab in the Department of Biochemistry sheds light on how transcription termination in eukaryotes is controlled.

Binding surfaces of elongation and termination factors on Pol II overlap. Pol II crystal structure with Spt4/5 (PDB ID: 5XON ) (pink) showing mapped positions of lysine-lysine cross-links (turquoise spheres) between Pol II subunits (grey) and termination factor Seb1.

The findings, from Dr Vasilieva's group in collaboration with colleagues in the Department of Chemistry, are published in Cell Reports (1) and demonstrate that conserved mechanisms are used at different steps of transcription. The work will help to fill the gaps in our understanding of how RNA polymerase II is released at the end of transcription.

All three stages of the transcription cycle of mRNAs - initiation, elongation and termination - are tightly regulated. The multi-protein complex RNA polymerase II (Pol II) interacts with a different set of factors to regulate the transition between these stages. The factors modulate how Pol II behaves, changing its ability to interact with DNA, incorporate nucleotides or pause.

Find out more (Department of Biochemistry website)

Similar stories

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.

Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.